Hyperlipidemia Prescription Drugs Market to Develop Rapidly by 2026
Hyperlipidemia refers to abnormal elevation of lipids and/or lipoprotein levels. Risks associated with this condition include stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension, and cardiovascular diseases. Drugs which are used to treat hyperlipidemia either accelerate the elimination of lipoproteins from the body or decrease production of lipoproteins. These drugs not only lower the unwanted cholesterol levels but are vital for lowering the risk of heart attacks or strokes. Primary causes of this disease include sedentary lifestyle, increase in alcohol consumption, and changes in dietary pattern. Additionally, increase in consumption of red meats, fried & processed foods, sugar, and rich foods increase blood cholesterol levels.
Read Report Overview: https://www.transparencymarketresearch.com/hyperlipidemia-prescription-drugs.html
The global hyperlipidemia prescription drugs market is estimated to expand substantially due to rise in susceptibility to heart diseases associated with the aging population. Other factors such as patent expiration and availability of funding, undertaking of health awareness programs by health care centers, high incidence rate of cardiovascular diseases, and rising awareness among people about reducing the harmful cholesterol levels to control heart diseases are projected to drive the market during the forecast period. A large number of hyperlipidemia drugs are in phase III of clinical trials for their assessment in providing clinical benefits and long-term safety records.
The global hyperlipidemia prescription drugs market can be segmented based on drug class, end-user, and region. In terms of drug class, the hyperlipidemia prescription drugs market can be classified into HMG COA reductase inhibitors, fibric acid derivatives, nicotinic acids, bile acid sequestrating agents, cholesterol absorption inhibitors, and others. Based on end-user, the hyperlipidemia prescription drugs market can be categorized into hospitals and clinics. In terms of region, the global hyperlipidemia prescription drugs market can be divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The hyperlipidemia prescription drugs market in each region is sub-divided into specific countries such as the U.S., Canada, Germany, the U.K., Brazil, China, India, Japan, and GCC countries.
Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1604
North America dominates the global hyperlipidemia prescription drugs market, followed by Europe due to high prevalence of diseases associated with elevated levels of lipoproteins and growing baby boomer population. According to the Centers for Disease Control and Prevention (CDC), every year about 630,000 people succumb to heart diseases in the U.S. Annually 1,055,000 people in the U.S. are victims of heart attacks. Of these cases 720,000 are a first heart attack and 335,000 happen to people who have already had a first heart attack. Asia Pacific is estimated to be a highly attractive region of the market during the forecast period due to highly developed health care infrastructure, and higher adoption rate of technologically advanced therapeutic products. Additionally, rise in aging population and increase in awareness about heart disease are some factors fueling the hyperlipidemia prescription drugs market.
Key players operating in the global hyperlipidemia prescription drugs market include Amgen, Inc., Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals Limited, Isis Pharmaceuticals, Inc., Merck & Co., Inc., Dr. Reddy\’s Laboratories Limited, Immuron Limited, Esperion Therapeutics, Inc., Pfizer, Inc., and Formac Pharmaceuticals N.V. Major players actively engage in various growth strategies such as collaborations, partnerships, agreements, and product launches to gain a competitive advantage in the market.
Request For TOC : https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=1604
About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453